CAC
ALNY icon

Cowen and Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cowen and Company’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-436
Closed -$61.9K – 656
2022
Q1 		$71K Buy
+436
New +$66.4K 0.01% 304
2021
Q2 		– Sell
-268
Closed -$39.3K – 588
2021
Q1 		$38K Buy
+268
New +$40.3K ﹤0.01% 411

Other funds holding ALNY

Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Cowen and Company's ALNY Position: Q2 2022 in Review

Cowen and Company sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2022, closing a stake of 436 shares — an estimated $61.9K sold.

Cowen and Company first reported a position in ALNY in Q1 2021 and held it in 2 quarters. The position peaked at $71K in Q1 2022. 423 funds tracked by Wall St. Rank hold ALNY as of Q2 2022.

  • Cowen and Company reported no remaining Alnylam Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Cowen and Company sold 436 Alnylam Pharmaceuticals shares in Q2 2022, an estimated $61.9K.
  • Cowen and Company first reported a position in Alnylam Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Cowen and Company's Alnylam Pharmaceuticals position peaked at $71K in Q1 2022.
  • 423 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2022.

Based on Cowen and Company's 13F filing for Q2 2022, filed 5 Aug 2022.